A Phase 2 interventional study of Rayaldee and Placebo in COVID-19, Coronavirus and SARS-CoV2 Infection, sponsored by OPKO Health, Inc.. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-28.
Sponsored by OPKO Health, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.
Among the 1,859 studies in COVID-19 with a site in United States, this one is the 516th largest by enrollment of the 1,321 interventional ones that give a count, is one of 818 that started in 2020, is one of 349 in phase 2, and was the 674th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
Shionogi · Sites in United States, Bulgaria, Japan
Ages 12+
ModernaTX, Inc. · Sites in United States, Argentina, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,859 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 240 · Phase 2 481 · Phase 3 244 · Phase 4 60
First in 2007; this study’s year is marked. 818 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 171 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 91 across the 1,321 interventional studies, 300 across the 521 observational. Of the 1,414 that completed or were terminated, 720 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
638 of 1,859 have an industry lead sponsor. The 10 most frequent:
OPKO Health, Inc. is the lead sponsor of 49 studies on the registry; 2 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 7 (78%) have results posted.
OPKO Health, Inc. has 2 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
85 of the studies in COVID-19 with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 85 to your calendar (.ics) → With an account.
Among the 1,859 studies in COVID-19 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase 2, single or multi-center, randomized, double-blind placebo-controlled study to evaluate the safety and efficacy of Rayaldee (CTAP101 Capsules) to treat adult subjects with mild to moderate COVID-19 who test positive for SARS-CoV-2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will be instructed to take a loading dose of 10 capsules (300 mcg) of study drug per day on Days 1, 2 and 3 at bedtime after fasting for at least 3 hours following dinner, with any nonalcoholic liquid, by the oral route. On Days 4-27, subjects will take a maintenance dose of 2 capsules per day at bedtime unless otherwise directed. Patients were to remain fasted for at least 3 hours after administration of study drug.
Drug: Rayaldee
Subjects will be instructed to take a loading dose of 10 capsules (0 mcg) of study drug per day on Days 1, 2 and 3 at bedtime after fasting for at least 3 hours following dinner, with any nonalcoholic liquid, by the oral route. On Days 4-27, subjects will take a maintenance dose of 2 capsules per day at bedtime unless otherwise directed. Patients were to remain fasted for at least 3 hours after administration of study drug.
Drug: Placebo
30 mcg calcifediol Extended-Release (ER) Capsule
Also known as: CTAP101 Capsule
0 mcg calcifediol Extended-Release (ER) Capsule
Concentration of Serum Total 25-hydroxyvitamin D Attained at or Above 50 ng/mL at Visit 3 (Day 14).
Number and percentage of subjects with serum total 25-hydroxyvitamin D attained at or above 50 ng/mL at Visit 3 (Day 14)
Time frame: 14 days
Resolution of COVID-19 Five Aggregated Symptoms Using the Flu-PRO Plus© Questionnaire.
The FLU- PRO Plus© questionnaire was specifically designed and validated to evaluate in clinical trials the presence, severity and duration of symptoms associated with viral infections. It contains 32 items (eg, felt hot, sweating, headache), grouped into 6 domains, that provide a comprehensive evaluation of such symptoms, using 5-point scales (values ranging from 0 to 4) with higher scores indicating worse symptoms. The number of days to resolution of the selected five COVID-19 symptoms (trouble breathing, chest congestion, dry or hacking cough, body aches and pains, and chills and shivering), defined as a reduction in the aggregate symptom score recorded on Day 0 (prior to study drug initiation) by the FLU-PRO Plus© questionnaire to or below 5 for a minimum of three consecutive days. Flu-PRO Plus© was created and supplied by Dr. John Powers and Leidos Biomedical, and the National Institute for Allergy and Infectious Diseases (NIAID).
Time frame: 42 days
Time to Resolution of COVID-19 Five Aggregated Symptoms
The number of days to resolution of five symptoms (trouble breathing, chest congestion, dry or hacking cough, body aches and pains, and chills and shivering), as measured by the FLU-PRO Plus© questionnaire, with resolution defined as the first aggregate symptom score of ≤5 which is maintained for a minimum of three consecutive days, with no individual symptom score \>1
Time frame: 42 days
Number of Subjects Who Had an COVID-19 Five Aggregated Symptoms Score >5 at Baseline Who Experienced Symptom Resolution as of Day 10
Resolution, defined as the first score of ≤5 which was maintained for a minimum of three consecutive days (without subsequent relapse), for the aggregate five COVID-19 symptoms (trouble breathing, chest congestion, dry or hacking cough, body aches and pains, and chills and shivering) and for each individual symptom, defined as a score of 0 or 1, as measured by the FLU-PRO Plus© questionnaire as of Day 10
Time frame: 10 days
Proportion of Subjects Who Had an COVID-19 Five Aggregated Symptoms Score >5 at Baseline Who Experienced Symptom Resolution as of Day 10
Resolution, defined as the first score of ≤5 which was maintained for a minimum of three consecutive days (without subsequent relapse), for the aggregate five COVID-19 symptoms (trouble breathing, chest congestion, dry or hacking cough, body aches and pains, and chills and shivering) and for each individual symptom, defined as a score of 0 or 1, as measured by the FLU-PRO Plus© questionnaire as of Day 10. Logistic regression with treatment as the main effect, and baseline aggregate symptom score, baseline 25D level, and body weight as covariates.
Time frame: 10 days
Number of Participants With Emergency Room/Urgent Care Visits
Number and percentage of subjects with emergency room/urgent care visits
Time frame: 42 days
Number of Participants With Oxygen Saturation Below 94% (Without Supplemental Oxygen)
Number and percentage of subjects with oxygen saturation below 94% (without supplemental oxygen)
Time frame: 42 days
Number of Participants With Hospitalizations
Number and percentage of subjects with hospitalization
Time frame: 42 days
Number of Participants With the Requirement for Mechanical Ventilation
Number and percentage of subjects requiring mechanical ventilation
Time frame: 42 days
Number of Participant Deaths
Number and percentage of subjects who died
Time frame: 42 days
Severity of COVID-19 Illness as Evidenced by Quality of Life Measures Using the FLU-PRO Plus Questionnaire
Quality-of-Life (QOL) responses are based on the number of non-missing observations within individual QOL question and visit. Comparisons to baseline are assessed only for subjects who were at risk for improvement. Percentages for the comparisons to baseline are based on the number at-risk for improvement.
Time frame: 14 days
Resolution of Symptoms Based on FLU-PRO Plus© COVID-19 Five Symptom Aggregate Score Based on Serum 25D Level Over the Treatment Period
Clinical course of COVID-19 as a function of Serum Total 25-hydroxyvitamin D concentrations of \<50 ng/mL, 50 to 100 ng/mL and \>100 ng/mL at Day 14, defined as the proportion of subjects in each treatment group with a total score of ≤5 for the selected five COVID-19 symptoms (trouble breathing, chest congestion, dry or hacking cough, body aches and pains, and chills and shivering) using the FLU-PRO Plus© questionnaire. Results were similar for comparisons between treatment groups on Days 7, 14, 21 and 28, and only data for Day 14 is presented.
Time frame: 14 days
| Milestone | Rayaldee | Placebo |
|---|---|---|
| Started | 85 | 86 |
| Completed | 70 | 71 |
| Not completed | 15 | 15 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Withdrawal by subject | 10 | 10 |
| Withdrew: Did not receive the study drug | 3 | 4 |
Number and percentage of subjects with serum total 25-hydroxyvitamin D attained at or above 50 ng/mL at Visit 3 (Day 14)
| Participants | Rayaldee | Placebo |
|---|---|---|
| Concentration of Serum Total 25-hydroxyvitamin D Attained at or Above 50 ng/mL at Visit 3 (Day 14). | 51 | 10 |
The FLU- PRO Plus© questionnaire was specifically designed and validated to evaluate in clinical trials the presence, severity and duration of symptoms associated with viral infections. It contains 32 items (eg, felt hot, sweating, headache), grouped into 6 domains, that provide a comprehensive evaluation of such symptoms, using 5-point scales (values ranging from 0 to 4) with higher scores indicating worse symptoms. The number of days to resolution of the selected five COVID-19 symptoms (trouble breathing, chest congestion, dry or hacking cough, body aches and pains, and chills and shivering), defined as a reduction in the aggregate symptom score recorded on Day 0 (prior to study drug initiation) by the FLU-PRO Plus© questionnaire to or below 5 for a minimum of three consecutive days. Flu-PRO Plus© was created and supplied by Dr. John Powers and Leidos Biomedical, and the National Institute for Allergy and Infectious Diseases (NIAID).
| days | Rayaldee | Placebo |
|---|---|---|
| Resolution of COVID-19 Five Aggregated Symptoms Using the Flu-PRO Plus© Questionnaire. | 9.8 ± 8.15 | 10.8 ± 9.54 |
The number of days to resolution of five symptoms (trouble breathing, chest congestion, dry or hacking cough, body aches and pains, and chills and shivering), as measured by the FLU-PRO Plus© questionnaire, with resolution defined as the first aggregate symptom score of ≤5 which is maintained for a minimum of three consecutive days, with no individual symptom score \>1
| days | Rayaldee | Placebo |
|---|---|---|
| Time to Resolution of COVID-19 Five Aggregated Symptoms | 12.0 ± 8.70 | 12.6 ± 9.09 |
Resolution, defined as the first score of ≤5 which was maintained for a minimum of three consecutive days (without subsequent relapse), for the aggregate five COVID-19 symptoms (trouble breathing, chest congestion, dry or hacking cough, body aches and pains, and chills and shivering) and for each individual symptom, defined as a score of 0 or 1, as measured by the FLU-PRO Plus© questionnaire as of Day 10
| Number of participants | Rayaldee | Placebo |
|---|---|---|
| Number of Subjects Who Had an COVID-19 Five Aggregated Symptoms Score >5 at Baseline Who Experienced Symptom Resolution as of Day 10 | 38 | 41 |
Resolution, defined as the first score of ≤5 which was maintained for a minimum of three consecutive days (without subsequent relapse), for the aggregate five COVID-19 symptoms (trouble breathing, chest congestion, dry or hacking cough, body aches and pains, and chills and shivering) and for each individual symptom, defined as a score of 0 or 1, as measured by the FLU-PRO Plus© questionnaire as of Day 10. Logistic regression with treatment as the main effect, and baseline aggregate symptom score, baseline 25D level, and body weight as covariates.
| Proportion | Rayaldee | Placebo |
|---|---|---|
| Proportion of Subjects Who Had an COVID-19 Five Aggregated Symptoms Score >5 at Baseline Who Experienced Symptom Resolution as of Day 10 | 0.618 | 0.592 |
Number and percentage of subjects with emergency room/urgent care visits
| Participants | Rayaldee | Placebo |
|---|---|---|
| Number of Participants With Emergency Room/Urgent Care Visits | 0 | 3 |
Number and percentage of subjects with oxygen saturation below 94% (without supplemental oxygen)
| Participants | Rayaldee | Placebo |
|---|---|---|
| Number of Participants With Oxygen Saturation Below 94% (Without Supplemental Oxygen) | 0 | 1 |
Number and percentage of subjects with hospitalization
| Participants | Rayaldee | Placebo |
|---|---|---|
| Number of Participants With Hospitalizations | 0 | 0 |
Number and percentage of subjects requiring mechanical ventilation
| Participants | Rayaldee | Placebo |
|---|---|---|
| Number of Participants With the Requirement for Mechanical Ventilation | 0 | 0 |
Number and percentage of subjects who died
| Participants | Rayaldee | Placebo |
|---|---|---|
| Number of Participant Deaths | 0 | 0 |
Quality-of-Life (QOL) responses are based on the number of non-missing observations within individual QOL question and visit. Comparisons to baseline are assessed only for subjects who were at risk for improvement. Percentages for the comparisons to baseline are based on the number at-risk for improvement.
| Participants | Rayaldee | Placebo |
|---|---|---|
| Overall, how severe were your infection symptoms today? — Improved compared to baseline | 47 | 48 |
| Overall, how severe were your infection symptoms today? — Worsened compared to baseline | 1 | 1 |
| Overall, how severe were your infection symptoms today? — No charge from baseline | 5 | 7 |
| Overall, how severe were your infection symptoms today? — Missing | 12 | 10 |
| Overall, how were your infection symptoms today compared to yesterday? — Improved compared to baseline | 45 | 50 |
| Overall, how were your infection symptoms today compared to yesterday? — Worsened compared to baseline | 0 | 1 |
| Overall, how were your infection symptoms today compared to yesterday? — No charge from baseline | 8 | 7 |
| Overall, how were your infection symptoms today compared to yesterday? — Missing | 12 | 10 |
| How much did your infection symptoms interfere with your usual activities today? — Improved compared to baseline | 48 | 52 |
| How much did your infection symptoms interfere with your usual activities today? — Worsened compared to baseline | 1 | 0 |
| How much did your infection symptoms interfere with your usual activities today? — No charge from baseline | 4 | 5 |
| How much did your infection symptoms interfere with your usual activities today? — Missing | 12 | 10 |
| Have you returned to your usual activities today? — Improved compared to baseline | 26 | 34 |
| Have you returned to your usual activities today? — Worsened compared to baseline | 0 | 0 |
| Have you returned to your usual activities today? — No charge from baseline | 26 | 24 |
| Have you returned to your usual activities today? — Missing | 12 | 10 |
| In general, how would you rate your physical health today? — Improved compared to baseline | 48 | 47 |
| In general, how would you rate your physical health today? — Worsened compared to baseline | 0 | 1 |
| In general, how would you rate your physical health today? — No charge from baseline | 5 | 10 |
| In general, how would you rate your physical health today? — Missing | 12 | 11 |
| Have you returned to your usual health today? — Improved compared to baseline | 19 | 19 |
| Have you returned to your usual health today? — Worsened compared to baseline | 0 | 0 |
| Have you returned to your usual health today? — No charge from baseline | 34 | 39 |
| Have you returned to your usual health today? — Missing | 12 | 10 |
Clinical course of COVID-19 as a function of Serum Total 25-hydroxyvitamin D concentrations of \<50 ng/mL, 50 to 100 ng/mL and \>100 ng/mL at Day 14, defined as the proportion of subjects in each treatment group with a total score of ≤5 for the selected five COVID-19 symptoms (trouble breathing, chest congestion, dry or hacking cough, body aches and pains, and chills and shivering) using the FLU-PRO Plus© questionnaire. Results were similar for comparisons between treatment groups on Days 7, 14, 21 and 28, and only data for Day 14 is presented.
| Participants | Rayaldee | Placebo |
|---|---|---|
| Serum 25D Level <50 ng/mL — Yes | 4 | 38 |
| Serum 25D Level <50 ng/mL — No | 6 | 17 |
| Serum 25D Level 50 - 100 ng/mL — Yes | 28 | 8 |
| Serum 25D Level 50 - 100 ng/mL — No | 8 | 2 |
| Serum 25D Level >100 ng/mL — Yes | 11 | 0 |
| Serum 25D Level >100 ng/mL — No | 4 | 0 |
Collected over 42 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rayaldee | 0/80 (0%) | 3/80 (3.8%) | 12/80 (15%) |
| Placebo | 0/80 (0%) | 1/80 (1.3%) | 12/80 (15%) |
| Event | Rayaldee | Placebo |
|---|---|---|
| COVID-19 pneumoniaInfections and infestations | 3/80 | 0/80 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 2/80 | 0/80 |
| COVID-19Infections and infestations | 0/80 | 1/80 |
| Event | Rayaldee | Placebo |
|---|---|---|
| COVID-19Infections and infestations | 0/80 | 5/80 |
| COVID-19 pneumoniaInfections and infestations | 3/80 | 1/80 |
| Transaminases increasedInvestigations | 2/80 | 0/80 |
| NauseaGastrointestinal disorders | 2/80 | 1/80 |
| HeadacheNervous system disorders | 1/80 | 2/80 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 2/80 | 0/80 |
| Herpes zosterInfections and infestations | 1/80 | 0/80 |
| SinusitisInfections and infestations | 0/80 | 1/80 |
| Electrocardiogram ST-T segment abnormalInvestigations | 1/80 | 1/80 |
| Blood parathyroid hormone increasedInvestigations | 1/80 | 0/80 |
Analysis is for the per protocol population, subjects who had a baseline aggregate five symptom score of \>5 and did not have a major protocol deviation prior to resolution.
| Age, Continuous(years) | Rayaldee | Placebo | Total |
|---|---|---|---|
| Mean | 42.1 ± 14.13 | 43.8 ± 14.32 | 43.0 ± 14.20 |
| Sex: Female, Male(Participants) | Rayaldee | Placebo | Total |
|---|---|---|---|
| Female | 38 | 41 | 79 |
| Male | 27 | 28 | 55 |
| Ethnicity (NIH/OMB)(Participants) | Rayaldee | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 55 | 56 | 111 |
| Not Hispanic or Latino | 10 | 13 | 23 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Rayaldee | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 7 | 3 | 10 |
| White | 58 | 65 | 123 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Height(cm) | Rayaldee | Placebo | Total |
|---|---|---|---|
| Mean | 167.91 ± 9.375 | 167.34 ± 8.747 | 167.62 ± 9.027 |
| Weight(kg) | Rayaldee | Placebo | Total |
|---|---|---|---|
| Mean | 81.05 ± 18.730 | 84.27 ± 18.985 | 82.71 ± 18.860 |
| BMI(kg/m2) | Rayaldee | Placebo | Total |
|---|---|---|---|
| Mean | 28.62 ± 5.521 | 29.99 ± 5.913 | 29.32 ± 5.746 |
| eGFR (glomerular filtration rate)(mL/min/1.73m^2) | Rayaldee | Placebo | Total |
|---|---|---|---|
| Mean | 97.5 ± 16.89 | 98.5 ± 18.62 | 98.0 ± 17.74 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2020 to primary completion in Oct 2021, 11 months.
Results were first posted in May 2024, 2 years 7 months after primary completion.
Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 11 months is above that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Modified-release Calcifediol Capsule